scholarly journals All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand

2016 ◽  
Vol 51 (10) ◽  
pp. 1400-1403 ◽  
Author(s):  
P Kruger ◽  
J Cooney ◽  
I Nivison-Smith ◽  
A Dodds ◽  
P Bardy ◽  
...  
Keyword(s):  
Stem Cell ◽  
Retrospective Study ◽  
New Zealand ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitors ◽  
Stem Cell Transplant ◽  
Blast Crisis ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant

scholarly journals A Rare Case of Chronic Myelogenous Leukemia Presenting as T-Cell Lymphoblastic Crisis

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Parikshit Padhi ◽  
Margarita Topalovski ◽  
Radwa El Behery ◽  
Eduardo S. Cantu ◽  
Ramadevi Medavarapu
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Chronic Myelogenous Leukemia ◽  
Stem Cell Transplant ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Blast Crisis ◽  
Myelogenous Leukemia ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant

Chronic Myelogenous Leukemia in blast crisis can manifest as either myeloid (more common) or lymphoid blast crisis. Most lymphoblastic crises are of B-cell lineage. T-cell blast crisis is extremely rare, with only a few reported cases. We present a case of a middle-aged man who was diagnosed with CML on peripheral blood and bone marrow biopsy. Because of a generalized lymphadenopathy noted at the time of diagnosis, a lymph node biopsy was also performed, which revealed a T-cell lymphoblastic leukemia/lymphoma, BCR/ABL1 positive, with clonal evolution. This is a very rare manifestation of CML in blast crisis with no standard treatment and with poor outcomes despite chemotherapy or allogeneic stem cell transplant. Given its rarity, it would be difficult to develop standard chemotherapy protocols. We believe the treatment for this condition should be similar to any lymphoid blast crisis. The patient was treated with induction chemotherapy (hyper-CVAD regimen) plus dasatinib for 3 cycles followed by sibling-donor allogeneic stem cell transplant and is currently on maintenance dasatinib and has minimal residual disease at this time.

Outcomes of non‐myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

2021 ◽  
Vol 51 (11) ◽  
pp. 1954-1958
Author(s):  
Phillip C. Nguyen ◽  
Kate Manos ◽  
Chun Y. Fong ◽  
Anthony P. Schwarer ◽  
Ing S. Tiong ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
First Remission ◽  
Acute Myeloid

Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study

2011 ◽  
Vol 53 (3) ◽  
pp. 503-505
Author(s):  
Vladimir Lazarevic ◽  
Mats Remberger ◽  
Hans Hägglund ◽  
Gunnar Juliusson ◽  
Hamdy Omar ◽  
...  
Keyword(s):  
Stem Cell ◽  
Retrospective Study ◽  
B Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Term Survival ◽  
Long Term Survival ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document